LAUSR

To investigate the risk factors for residual dizziness (RD) in patients with benign paroxysmal positional vertigo (BPPV) after successful repositioning. Searches were performed in PubMed, Embase, Cochrane library, Web of Science, Chinese National Knowledge Infrastructure, and Sino Med up to March 7, 2021 and references of relevant articles were screened. Data from eligible studies were meta-analyzed using Stata version 16.0 and Review Manager 5.4. In this systematic review and meta-analysis of 4487 patients from 31 studies, the prevalence of RD was 43.0% (95% CI 39.0–48.0%). Age (MD 4.17; 95% CI 2.13–6.21, P = 0.000), female gender (OR = 1.28, 95% CI 1.11–1.47, P = 0.001), secondary BPPV (OR 1.88; 95% CI 1.27–2.77, P = 0.001), a longer duration of BPPV before treatment (MD 3.45; 95% CI 1.87–5.02, P = 0.000), abnormal ocular vestibular evoked myogenic potential (OVEMP, OR 4.34; 95% CI 2.78–6.78, P = 0.000), abnormal cervical vestibular evoked myogenic potential (CVEMP, OR 2.48; 95% CI 1.54–3.99, P = 0.000), higher Dizziness Handicap Index (DHI) score before treatment (MD 10.88; 95% CI 5.96–15.80, P = 0.000), anxiety (OR 9.58; 95% CI 6.32–14.52, P = 0.000), osteopenia (OR = 4.40, 95% CI 2.17–8.96, P = 0.000), onset in winter (OR 7.27; 95% CI 2.38–22.24, P = 0.001) and with a history of BPPV (OR 1.79; 95% CI 1.06–3.04, P = 0.03) are the risk factors for RD in patients with BPPV after successful repositioning. The affected side, location or type of semicircular involvement, hyperlipidemia, diabetes, hypertension, heart disease, migraine, sleep disorders, canalolithiasis/cupulolithiasis, the number of times the canalith repositioning procedures (CRPs) were performed and number of vertigo attacks did not correlate with the occurrence of RD. Despite successful treatment, nearly half of the BPPV patients developed RD. RD seems to be a syndrome caused by multiple factors. The pathogenesis of most factors can be explained by psychological and/or physical disorders. Early recognition of these risk factors contributes to the prevention and treatment of RD.